| Molecular formula | C76H104N18O19S2 |
|---|
| Molecular weight | 1637.9 g/mol |
|---|
| Registered trials | 564 |
|---|
| PubChem CID | 16129706 |
|---|
What Somatostatin Is
Somatostatin is a peptide compound identified by PubChem CID 16129706, with a molecular formula of C76H104N18O19S2. No approved drug label is associated with this compound in the data reviewed, so no FDA-approved indications, mechanism statement, or brand names can be reported here. This monograph reflects its status as a compound studied in clinical research rather than an approved medication.
Trial Footprint
Somatostatin appears in 564 registered clinical trials. Sampled studies span several areas of clinical investigation. One completed Phase 4 trial compared endoscopic variceal ligation combined with a vasoconstrictor against ligation combined with a proton pump inhibitor for controlling acute esophageal variceal bleeding. Other completed studies without a designated phase examined dietary approaches in irritable bowel syndrome with a diarrheal variant, and the effects of diet on plasma chromogranin measurement in patients with neuroendocrine tumors. These entries illustrate the range of settings in which somatostatin has been studied, without indicating that any use is approved or established as effective.
FAQ
No approved label for somatostatin was found in the data reviewed for this monograph. It is discussed here as a compound studied in clinical research rather than as an approved medication.
Somatostatin is a peptide with the molecular formula C76H104N18O19S2. It is catalogued in PubChem under CID 16129706.
Public trial registries list 564 registered trials involving somatostatin. Sampled studies include research in variceal bleeding management, irritable bowel syndrome, and neuroendocrine tumor diagnostics.
Sampled trials include a completed Phase 4 study comparing treatment approaches for acute esophageal variceal bleeding, and completed studies examining dietary factors in irritable bowel syndrome and in neuroendocrine tumor patients. These are examples from a much larger set of registered trials.
No adverse event report data was available in the dataset used for this monograph, so no side effect summary can be provided here.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov
Updated 2026-08-10